22 September 2011
|
With patent protection over some of the world’s most expensive drugs nearing their expiry date or in (some/many) cases having already expired, the race to create copies of these drugs to be sold at far cheaper prices is well and truly underway.
In this Boardroom Radio interview, Wayne Condon and Dr Stuart Boyer discuss this ‘biosimilars’ development and how this will affect the Australian market.
|
Click here for the full interview.
|
|
Brought to you in partnership with Boardroom Radio Australia
|
